Skip to main content
NANOSONICS LIMITED logo

NANOSONICS LIMITED — Investor Relations & Filings

Ticker · NAN ISIN · AU000000NAN9 LEI · 549300XUBCM70BRANN81 ASX Manufacturing
Open in API
Filings indexed 1,048 across all filing types
Latest filing 2014-07-07 Director's Dealing
Country AU Australia
Listing ASX NAN

About NANOSONICS LIMITED

https://www.nanosonics.com.au

Nanosonics Limited is a medical technology company specializing in the development and commercialization of infection prevention solutions. The company's flagship product, the trophon system, provides automated high-level disinfection (HLD) for ultrasound probes. Utilizing a proprietary hydrogen peroxide mist technology, the trophon device ensures consistent and effective disinfection of both the probe handle and shaft, addressing the risks of cross-contamination in clinical settings. The system is designed to integrate into diagnostic workflows, offering a faster and more environmentally sustainable alternative to traditional manual chemical soaking methods. Nanosonics continues to expand its portfolio with digital traceability tools and audit-ready reporting software to enhance compliance and patient safety across global healthcare facilities.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 4 pages 71.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and details changes in securities held by a company director, including exercising options and selling shares. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure about insider transactions. The content focuses on personal share transactions by a director, not financial results, management changes, or other report types. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives. The document length and content confirm it is not a brief announcement or a report publication notice but a full disclosure notice. Therefore, the correct classification is DIRS with high confidence.
2014-07-07 English
Ceasing to be a substantial holder 2 pages 169.5KB
Major Shareholding Notification Classification · 100% confidence The document is a notice titled 'Ceasing to be a substantial holder' and references a Form 605, which is a regulatory form used to notify changes in substantial shareholding. The content is brief and does not contain financial statements or detailed analysis. It is an announcement of a change in significant share ownership levels, fitting the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding status, not a report or financial disclosure.
2014-06-22 English
Appendix 3B 7 pages 117.8KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed announcement regarding the exercise of employee share options and the issuance of new shares under the Nanosonics Employee Share Option Plan. It includes a formal Appendix 3B, which is a standard ASX form for new issue announcements and applications for quotation of additional securities. The document contains specific details about the number and class of securities issued, exercise prices, expiry dates, and compliance with relevant sections of the Corporations Act. It is not a financial report, earnings release, or management discussion but rather a regulatory announcement about capital changes and securities issuance. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement or a report publication notice but a substantive filing about share issuance.
2014-06-18 English
Nanosonics Shareholder Report - May 2014 4 pages 1.1MB
Interim / Quarterly Report Classification · 95% confidence The document is titled as a 'shareholder quarterly report' and contains detailed discussion of quarterly sales figures, business developments, strategic partnerships, and clinical evidence supporting the company's product. It includes substantive financial data such as sales figures for the quarter ended March 31, 2014, and year-to-date sales, indicating it is a comprehensive financial report for a period shorter than a full fiscal year. The length of the document (over 10,000 characters) and the presence of detailed financial and operational information confirm it is not merely an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2014
2014-05-22 English
Trophon EPR included in new AIUM guidelines 2 pages 120.7KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 19 May 2014 from Nanosonics Limited, discussing the inclusion of their product trophon EPR in new guidelines from the American Institute of Ultrasound in Medicine (AIUM). It highlights the significance of this inclusion for market positioning and regulatory trends. The text is a press release style announcement about a product and regulatory guideline update, not a financial report, earnings release, or management discussion. It does not contain financial data, voting results, or legal proceedings. The document length is 4075 characters, which is relatively short and consistent with an announcement rather than a detailed report. There is no indication that this is an Annual Report, Interim Report, or any other formal financial filing. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2014-05-18 English
Appendix 4C - quarterly 6 pages 101.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "Quarterly Report (4C Statement) for Quarter ended 31 March 2014" and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, reconciliation of cash, and compliance statement signed by the CEO. It reports on sales revenue, cash reserves, and operational highlights for the quarter and year to date. The presence of an Appendix 4C statement and detailed quarterly financial data confirms this is a comprehensive interim financial report for a period shorter than a full fiscal year. The document also includes an investor conference call announcement, but the main content is the quarterly financial report itself, not just an announcement or transcript. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2014
2014-04-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.